<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970941</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0084</org_study_id>
    <nct_id>NCT03970941</nct_id>
  </id_info>
  <brief_title>Two-stage Treatment of Large Bone Defects With Cerament® G and Cerament® V Plus Auto and/or Allograft Using the Masquelet Technique as Salvage Therapy After Bone Resection in Patients With Septic Pseudarthrosis</brief_title>
  <acronym>EVIDENCE</acronym>
  <official_title>Two-stage Treatment of Large Bone Defects With Cerament® G and Cerament® V Plus Auto and/or Allograft Using the Masquelet Technique as Salvage Therapy After Bone Resection in Patients With Septic Pseudarthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic pseudarthrosis of long bones are complications that can unfortunately occur after the
      consolidation of a fracture and some situations present risks of superinfection, persistent
      infection or mechanical failure (30-40% risk of complications) that can lead to amputation.

      A possible saving situation used by CRIOAC (&quot;Centre de Référence des Infections
      Ostéo-Articulaires Complexes&quot;) is the use of a bone substitute impregnated with an antibiotic
      allowing a high local concentration of this antibiotic.

      The aim of this study is to evaluate the cost of management of septic pseudarthrosis with
      two-stage treatment and CERAMENT® and the quality of life for this patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cost evaluation</measure>
    <time_frame>24 months maximum</time_frame>
    <description>Estimation of the cost of care from the point of view of the hospital This estimation will be measured at the end of patient follow-up (usually between 12 and 24 months after antibiotic therapy disruption)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pseudarthrosis</condition>
  <arm_group>
    <arm_group_label>CERAMENT</arm_group_label>
    <description>Patients having a septic pseudarthrosis managed with two-stage treatment (Masquelet Technique) with CERAMENT®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO CERAMENT COMPARATIVE COHORT</arm_group_label>
    <description>Patients having had a septic pseudarthrosis managed with two-stage treatment (only Masquelet Technique) without CERAMENT®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cost evaluation</intervention_name>
    <description>The cost for the hospital of the strategy of management will be evaluated.</description>
    <arm_group_label>CERAMENT</arm_group_label>
    <arm_group_label>NO CERAMENT COMPARATIVE COHORT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>The quality of life of patients will be measured.</description>
    <arm_group_label>CERAMENT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients having / having had a septic pseudarthrosis manage with two stage exchange
        (Masquelet technique)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 years old

          -  Diagnosis of septic pseudarthrosis

          -  septic pseudarthrosis managed by the surgical technique using the CERAMENT bone
             substitute combined with an autograft / allograft by the Masquelet technique OR, for
             the comparative cohort: septic pseudarthrosis on long bone previously managed by the
             masquelet method without CERAMENT®

          -  Medico-surgical management within the CRIOAC (&quot;Centre de Référence des Infections
             Ostéo-Articulaires Complexes&quot;) of the Croix-Rousse hospital in Lyon

          -  Patient who was informed and did not object to participate in the study

        Exclusion Criteria:

          -  Patient with a disability (deafness, language disorders) or whose mental or cognitive
             state does not allow to be informed and to express his opposition if necessary.

          -  Patient with a disability (deafness, language impairment) or whose mental or cognitive
             state does not allow to understand the questions in the quality of life questionnaire

          -  Patient participating in another quality of life study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Tristan FERRY, MD, PhD</last_name>
    <phone>0472071107</phone>
    <phone_ext>+33</phone_ext>
    <email>tristan.ferry@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugénie MABRUT, ARC</last_name>
    <phone>0426732938</phone>
    <phone_ext>+33</phone_ext>
    <email>eugenie.mabrut@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Référence des Infections Ostéo-Articulaires complexes (CRIOAc) - Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Tristan FERRY, MD, PhD</last_name>
      <phone>0472071107</phone>
      <phone_ext>+33</phone_ext>
      <email>tristan.ferry@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eugénie MABRUT, ARC</last_name>
      <phone>0426732938</phone>
      <phone_ext>+33</phone_ext>
      <email>eugenie.mabrut@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudarthrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

